Cargando…

Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection

Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedegah, Martha, Porter, Chad, Goguet, Emilie, Ganeshan, Harini, Belmonte, Maria, Huang, Jun, Belmonte, Arnel, Inoue, Sandra, Acheampong, Neda, Malloy, Allison M. W., Hollis-Perry, Monique, Jackson-Thompson, Belinda, Ramsey, Kathy F., Alcorta, Yolanda, Maiolatesi, Santina E., Wang, Gregory, Reyes, Anatolio E., Illinik, Luca, Sanchez-Edwards, Margaret, Burgess, Timothy H., Broder, Christopher C., Laing, Eric D., Pollett, Simon D., Villasante, Eileen, Mitre, Edward, Hollingdale, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576055/
https://www.ncbi.nlm.nih.gov/pubmed/36251675
http://dx.doi.org/10.1371/journal.pone.0276241
_version_ 1784811446093217792
author Sedegah, Martha
Porter, Chad
Goguet, Emilie
Ganeshan, Harini
Belmonte, Maria
Huang, Jun
Belmonte, Arnel
Inoue, Sandra
Acheampong, Neda
Malloy, Allison M. W.
Hollis-Perry, Monique
Jackson-Thompson, Belinda
Ramsey, Kathy F.
Alcorta, Yolanda
Maiolatesi, Santina E.
Wang, Gregory
Reyes, Anatolio E.
Illinik, Luca
Sanchez-Edwards, Margaret
Burgess, Timothy H.
Broder, Christopher C.
Laing, Eric D.
Pollett, Simon D.
Villasante, Eileen
Mitre, Edward
Hollingdale, Michael R.
author_facet Sedegah, Martha
Porter, Chad
Goguet, Emilie
Ganeshan, Harini
Belmonte, Maria
Huang, Jun
Belmonte, Arnel
Inoue, Sandra
Acheampong, Neda
Malloy, Allison M. W.
Hollis-Perry, Monique
Jackson-Thompson, Belinda
Ramsey, Kathy F.
Alcorta, Yolanda
Maiolatesi, Santina E.
Wang, Gregory
Reyes, Anatolio E.
Illinik, Luca
Sanchez-Edwards, Margaret
Burgess, Timothy H.
Broder, Christopher C.
Laing, Eric D.
Pollett, Simon D.
Villasante, Eileen
Mitre, Edward
Hollingdale, Michael R.
author_sort Sedegah, Martha
collection PubMed
description Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infection vaccination (‘hybrid immunity’) further augments this immunity To accomplish these goals, we studied healthy adult healthcare workers who were (a) uninfected and unvaccinated (n = 12), (b) uninfected and vaccinated with Pfizer-BioNTech BNT162b2 vaccine (2 doses n = 177, one dose n = 1) or Moderna mRNA-1273 vaccine (one dose, n = 1), and (c) previously infected with SARS-CoV-2 and vaccinated (BNT162b2, two doses, n = 6, one dose n = 1; mRNA-1273 two doses, n = 1). Infection status was determined by repeated PCR testing of participants. We used FluoroSpot Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) assays, using subpools of 15-mer peptides covering the S (10 subpools), N (4 subpools) and M (2 subpools) proteins. Responses were expressed as frequencies (percent positive responders) and magnitudes (spot forming cells/10(6) cytokine-producing peripheral blood mononuclear cells [PBMCs]). Almost all vaccinated participants with no prior infection exhibited IFN-γ, IL-2 and IFN-γ+IL2 responses to S glycoprotein subpools (89%, 93% and 27%, respectively) mainly directed to the S2 subunit and were more robust than responses to the N or M subpools. However, in previously infected and vaccinated participants IFN-γ, IL-2 and IFN-γ+IL2 responses to S subpools (100%, 100%, 88%) were substantially higher than vaccinated participants with no prior infection and were broader and directed against nine of the 10 S glycoprotein subpools spanning the S1 and S2 subunits, and all the N and M subpools. 50% of uninfected and unvaccinated individuals had IFN-γ but not IL2 or IFN-γ+IL2 responses against one S and one M subpools that were not increased after vaccination of uninfected or SARS-CoV-2-infected participants. Summed IFN-γ, IL-2, and IFN-γ+IL2 responses to S correlated with IgG responses to the S glycoprotein. These studies demonstrated that vaccinations with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein, and that individuals that are vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins.
format Online
Article
Text
id pubmed-9576055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95760552022-10-18 Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection Sedegah, Martha Porter, Chad Goguet, Emilie Ganeshan, Harini Belmonte, Maria Huang, Jun Belmonte, Arnel Inoue, Sandra Acheampong, Neda Malloy, Allison M. W. Hollis-Perry, Monique Jackson-Thompson, Belinda Ramsey, Kathy F. Alcorta, Yolanda Maiolatesi, Santina E. Wang, Gregory Reyes, Anatolio E. Illinik, Luca Sanchez-Edwards, Margaret Burgess, Timothy H. Broder, Christopher C. Laing, Eric D. Pollett, Simon D. Villasante, Eileen Mitre, Edward Hollingdale, Michael R. PLoS One Research Article Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infection vaccination (‘hybrid immunity’) further augments this immunity To accomplish these goals, we studied healthy adult healthcare workers who were (a) uninfected and unvaccinated (n = 12), (b) uninfected and vaccinated with Pfizer-BioNTech BNT162b2 vaccine (2 doses n = 177, one dose n = 1) or Moderna mRNA-1273 vaccine (one dose, n = 1), and (c) previously infected with SARS-CoV-2 and vaccinated (BNT162b2, two doses, n = 6, one dose n = 1; mRNA-1273 two doses, n = 1). Infection status was determined by repeated PCR testing of participants. We used FluoroSpot Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) assays, using subpools of 15-mer peptides covering the S (10 subpools), N (4 subpools) and M (2 subpools) proteins. Responses were expressed as frequencies (percent positive responders) and magnitudes (spot forming cells/10(6) cytokine-producing peripheral blood mononuclear cells [PBMCs]). Almost all vaccinated participants with no prior infection exhibited IFN-γ, IL-2 and IFN-γ+IL2 responses to S glycoprotein subpools (89%, 93% and 27%, respectively) mainly directed to the S2 subunit and were more robust than responses to the N or M subpools. However, in previously infected and vaccinated participants IFN-γ, IL-2 and IFN-γ+IL2 responses to S subpools (100%, 100%, 88%) were substantially higher than vaccinated participants with no prior infection and were broader and directed against nine of the 10 S glycoprotein subpools spanning the S1 and S2 subunits, and all the N and M subpools. 50% of uninfected and unvaccinated individuals had IFN-γ but not IL2 or IFN-γ+IL2 responses against one S and one M subpools that were not increased after vaccination of uninfected or SARS-CoV-2-infected participants. Summed IFN-γ, IL-2, and IFN-γ+IL2 responses to S correlated with IgG responses to the S glycoprotein. These studies demonstrated that vaccinations with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein, and that individuals that are vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins. Public Library of Science 2022-10-17 /pmc/articles/PMC9576055/ /pubmed/36251675 http://dx.doi.org/10.1371/journal.pone.0276241 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Sedegah, Martha
Porter, Chad
Goguet, Emilie
Ganeshan, Harini
Belmonte, Maria
Huang, Jun
Belmonte, Arnel
Inoue, Sandra
Acheampong, Neda
Malloy, Allison M. W.
Hollis-Perry, Monique
Jackson-Thompson, Belinda
Ramsey, Kathy F.
Alcorta, Yolanda
Maiolatesi, Santina E.
Wang, Gregory
Reyes, Anatolio E.
Illinik, Luca
Sanchez-Edwards, Margaret
Burgess, Timothy H.
Broder, Christopher C.
Laing, Eric D.
Pollett, Simon D.
Villasante, Eileen
Mitre, Edward
Hollingdale, Michael R.
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
title Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
title_full Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
title_fullStr Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
title_full_unstemmed Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
title_short Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
title_sort cellular interferon-gamma and interleukin-2 responses to sars-cov-2 structural proteins are broader and higher in those vaccinated after sars-cov-2 infection compared to vaccinees without prior sars-cov-2 infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576055/
https://www.ncbi.nlm.nih.gov/pubmed/36251675
http://dx.doi.org/10.1371/journal.pone.0276241
work_keys_str_mv AT sedegahmartha cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT porterchad cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT goguetemilie cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT ganeshanharini cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT belmontemaria cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT huangjun cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT belmontearnel cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT inouesandra cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT acheampongneda cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT malloyallisonmw cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT hollisperrymonique cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT jacksonthompsonbelinda cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT ramseykathyf cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT alcortayolanda cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT maiolatesisantinae cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT wanggregory cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT reyesanatolioe cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT illinikluca cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT sanchezedwardsmargaret cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT burgesstimothyh cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT broderchristopherc cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT laingericd cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT pollettsimond cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT villasanteeileen cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT mitreedward cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection
AT hollingdalemichaelr cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection